Stock Analysis on Net

Elevance Health Inc. (NYSE:ELV)

$24.99

DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin
Quarterly Data

Microsoft Excel

Paying user area

The data is hidden behind: . Unhide it.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Two-Component Disaggregation of ROE

Elevance Health Inc., decomposition of ROE (quarterly data)

Microsoft Excel
ROE = ROA × Financial Leverage
Dec 31, 2025 = ×
Sep 30, 2025 = ×
Jun 30, 2025 = ×
Mar 31, 2025 = ×
Dec 31, 2024 = ×
Sep 30, 2024 = ×
Jun 30, 2024 = ×
Mar 31, 2024 = ×
Dec 31, 2023 = ×
Sep 30, 2023 = ×
Jun 30, 2023 = ×
Mar 31, 2023 = ×
Dec 31, 2022 = ×
Sep 30, 2022 = ×
Jun 30, 2022 = ×
Mar 31, 2022 = ×

Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).


The financial performance, as indicated by the two-component DuPont analysis, reveals a generally declining trend in profitability and a fluctuating, but overall decreasing, level of financial leverage over the observed period. Return on Equity (ROE) demonstrates a consistent decrease from 17.36% in March 2022 to 12.90% in December 2025. This decline is attributable to both a reduction in Return on Assets (ROA) and a moderate decrease in Financial Leverage.

Return on Assets (ROA)
ROA experienced a gradual decline throughout the period, starting at 6.21% in March 2022 and decreasing to 4.66% by December 2025. While there were minor fluctuations, the overall trajectory is downward, suggesting a diminishing ability to generate earnings from its asset base. The most significant drops occurred between September 2024 and March 2025, and again between March 2025 and June 2025. The period between March 2022 and December 2022 saw a relatively stable ROA, followed by a more pronounced decline beginning in March 2023.
Financial Leverage
Financial Leverage exhibited more variability than ROA. It began at 2.79 in March 2022, peaked at 2.92 in March 2023, and then generally decreased to 2.77 in December 2025. The decrease in leverage suggests a reduction in the use of debt financing relative to equity. The period from June 2023 to December 2023 shows a notable decrease in leverage, followed by a slight increase in March 2024 before resuming the downward trend.
Return on Equity (ROE)
ROE’s decline mirrors the combined effect of the trends in ROA and Financial Leverage. The initial decrease from March 2022 to December 2022 was relatively moderate. However, the period from March 2023 to December 2025 shows a more substantial and consistent decline. The largest single-quarter decrease in ROE occurred between September 2025 and December 2025, coinciding with the lowest ROA value of the observed period.

In summary, the observed trends indicate a weakening in the company’s profitability, as measured by ROA, and a cautious approach to financial leverage. The resulting decline in ROE suggests a reduced return for shareholders over the analyzed timeframe. Further investigation into the underlying drivers of the ROA decline would be warranted.


Three-Component Disaggregation of ROE

Elevance Health Inc., decomposition of ROE (quarterly data)

Microsoft Excel
ROE = Net Profit Margin × Asset Turnover × Financial Leverage
Dec 31, 2025 = × ×
Sep 30, 2025 = × ×
Jun 30, 2025 = × ×
Mar 31, 2025 = × ×
Dec 31, 2024 = × ×
Sep 30, 2024 = × ×
Jun 30, 2024 = × ×
Mar 31, 2024 = × ×
Dec 31, 2023 = × ×
Sep 30, 2023 = × ×
Jun 30, 2023 = × ×
Mar 31, 2023 = × ×
Dec 31, 2022 = × ×
Sep 30, 2022 = × ×
Jun 30, 2022 = × ×
Mar 31, 2022 = × ×

Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).


The analysis of the provided financial metrics reveals evolving trends in profitability, efficiency, and financial leverage over the observed period. Return on Equity (ROE) demonstrates a general declining trend, though with some quarterly fluctuations. This trend is driven by changes in the constituent components of the DuPont analysis: Net Profit Margin, Asset Turnover, and Financial Leverage.

Net Profit Margin
The Net Profit Margin experienced a gradual decline from 4.37% in March 2022 to 2.87% in December 2025. While there were minor increases in certain quarters (e.g., March 2024, June 2024), the overall trajectory is downward. The most significant decrease occurred between June 2023 and December 2025, indicating increasing pressure on profitability. The margin decreased from 3.89% to 2.87% over this period.
Asset Turnover
Asset Turnover exhibited a relatively stable pattern with a slight upward trend overall. Beginning at 1.42 in March 2022, it increased to 1.63 in December 2025. The increases were incremental, with some quarterly variations. This suggests a consistent, though modest, improvement in the efficiency with which assets are used to generate revenue.
Financial Leverage
Financial Leverage fluctuated throughout the period, initially increasing from 2.79 in March 2022 to 2.92 in March 2023, before generally decreasing to 2.77 in December 2025. The highest leverage was observed in the first half of 2023. The decline in leverage suggests a reduction in the reliance on debt financing, or a change in the capital structure.

The initial decline in ROE from 17.36% in March 2022 to 15.23% in December 2022 was influenced by a combination of factors, including a decrease in Net Profit Margin and a slight reduction in Financial Leverage, partially offset by an increase in Asset Turnover. The continued decline in ROE through 2025 is primarily attributable to the consistent decrease in Net Profit Margin, despite improvements in Asset Turnover. The impact of decreasing Net Profit Margin outweighed the positive effect of increased Asset Turnover and the fluctuations in Financial Leverage. The most substantial decrease in ROE occurred between March 2024 and December 2025, coinciding with the most significant drop in Net Profit Margin.

In summary, while asset utilization improved, the declining profitability significantly impacted overall returns to equity holders. The observed trends suggest a need to investigate the factors contributing to the decreasing Net Profit Margin to mitigate further declines in ROE.


Five-Component Disaggregation of ROE

Elevance Health Inc., decomposition of ROE (quarterly data)

Microsoft Excel
ROE = Tax Burden × Interest Burden × EBIT Margin × Asset Turnover × Financial Leverage
Dec 31, 2025 = × × × ×
Sep 30, 2025 = × × × ×
Jun 30, 2025 = × × × ×
Mar 31, 2025 = × × × ×
Dec 31, 2024 = × × × ×
Sep 30, 2024 = × × × ×
Jun 30, 2024 = × × × ×
Mar 31, 2024 = × × × ×
Dec 31, 2023 = × × × ×
Sep 30, 2023 = × × × ×
Jun 30, 2023 = × × × ×
Mar 31, 2023 = × × × ×
Dec 31, 2022 = × × × ×
Sep 30, 2022 = × × × ×
Jun 30, 2022 = × × × ×
Mar 31, 2022 = × × × ×

Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).


The five-component DuPont analysis reveals several trends in the company’s performance over the observed period. Overall, Return on Equity (ROE) demonstrates a declining trend from 17.36% in March 2022 to 12.90% in December 2025. This decline is attributable to shifts in the underlying components, particularly the EBIT Margin and Financial Leverage, though partially offset by changes in Asset Turnover.

Tax Burden
The Tax Burden remained consistently high, fluctuating between 0.77 and 0.84. A slight upward trend is observed towards the end of the period, increasing from 0.77 in March 2022 to 0.84 in December 2025. This suggests a potentially increasing effective tax rate or a shift in the company’s earnings mix.
Interest Burden
The Interest Burden generally decreased over the period, moving from 0.91 in March 2022 to 0.83 in December 2025. This indicates improved capacity to cover interest expenses, potentially due to debt restructuring or increased earnings before interest and taxes. The decline is gradual, with minor fluctuations throughout the observed timeframe.
EBIT Margin
The EBIT Margin experienced a notable decline. Starting at 6.24% in March 2022, it decreased to 4.11% in December 2025. The most significant drop occurred between March 2023 and December 2025, indicating increasing cost pressures or decreasing pricing power. While there were minor recoveries in some quarters, the overall trend is definitively downward.
Asset Turnover
Asset Turnover exhibited an increasing trend, rising from 1.42 in March 2022 to 1.63 in December 2025. This suggests improved efficiency in utilizing assets to generate revenue. The increase is relatively consistent, with a slight acceleration in the latter half of the period. This positive trend partially mitigates the negative impact of the declining EBIT Margin on ROE.
Financial Leverage
Financial Leverage initially increased from 2.79 in March 2022 to 2.92 in March 2023, then decreased to 2.77 in December 2025. The initial increase suggests a greater reliance on debt financing. The subsequent decline indicates a reduction in debt relative to equity, potentially through retained earnings or equity issuance. The decrease in leverage, while potentially reducing risk, also contributes to the overall decline in ROE.

In summary, the decline in ROE is primarily driven by the decreasing EBIT Margin and, to a lesser extent, the reduction in Financial Leverage. The increasing Asset Turnover provides a partial offset, demonstrating improved operational efficiency. The relatively stable Tax Burden and decreasing Interest Burden have limited impact on the overall ROE trend.


Two-Component Disaggregation of ROA

Elevance Health Inc., decomposition of ROA (quarterly data)

Microsoft Excel
ROA = Net Profit Margin × Asset Turnover
Dec 31, 2025 = ×
Sep 30, 2025 = ×
Jun 30, 2025 = ×
Mar 31, 2025 = ×
Dec 31, 2024 = ×
Sep 30, 2024 = ×
Jun 30, 2024 = ×
Mar 31, 2024 = ×
Dec 31, 2023 = ×
Sep 30, 2023 = ×
Jun 30, 2023 = ×
Mar 31, 2023 = ×
Dec 31, 2022 = ×
Sep 30, 2022 = ×
Jun 30, 2022 = ×
Mar 31, 2022 = ×

Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).


The financial performance, as disaggregated by the two-component DuPont analysis, reveals fluctuating trends in profitability and efficiency over the observed period. Net Profit Margin and Asset Turnover collectively drive Return on Assets (ROA), and their individual movements provide insight into the company’s operational dynamics.

Net Profit Margin
The Net Profit Margin demonstrates a general declining trend from 4.37% in March 2022 to 2.87% in December 2025. Initial values remained relatively stable through June 2022, followed by a gradual decrease throughout 2022 and 2023. A slight recovery is observed in March and June 2024, peaking at 3.93%, before resuming its downward trajectory through the end of the observation period. The most significant decline occurs between June 2024 and December 2025, indicating increasing cost pressures or decreasing revenue generation relative to sales.
Asset Turnover
Asset Turnover exhibits a more consistent upward trend overall, increasing from 1.42 in March 2022 to 1.63 in December 2025. The ratio experiences incremental gains throughout 2022 and 2023, suggesting improved efficiency in utilizing assets to generate revenue. While there are minor fluctuations, the trend remains positive, indicating the company is becoming more effective at converting investments in assets into sales. A slight dip is visible in the first half of 2024, but the upward momentum resumes in the latter half of the year.
Return on Assets (ROA)
ROA initially declines from 6.21% in March 2022 to 5.12% in December 2024, mirroring the influence of the decreasing Net Profit Margin. Despite the increasing Asset Turnover, the declining profitability exerts a stronger downward pressure on ROA. A modest recovery is then observed in the final two quarters, with ROA reaching 4.66% in December 2025. This suggests that the improved asset utilization partially offsets the impact of lower profit margins, but is not sufficient to return ROA to its earlier levels. The interplay between the two components highlights that while the company is becoming more efficient with its assets, its ability to generate profit from each dollar of sales is diminishing.

In summary, the analysis indicates a trade-off between profitability and efficiency. While the company demonstrates increasing efficiency in asset utilization, declining profit margins are negatively impacting overall returns. Continued monitoring of both Net Profit Margin and Asset Turnover is crucial to understanding the drivers of ROA and assessing the company’s long-term financial health.


Four-Component Disaggregation of ROA

Elevance Health Inc., decomposition of ROA (quarterly data)

Microsoft Excel
ROA = Tax Burden × Interest Burden × EBIT Margin × Asset Turnover
Dec 31, 2025 = × × ×
Sep 30, 2025 = × × ×
Jun 30, 2025 = × × ×
Mar 31, 2025 = × × ×
Dec 31, 2024 = × × ×
Sep 30, 2024 = × × ×
Jun 30, 2024 = × × ×
Mar 31, 2024 = × × ×
Dec 31, 2023 = × × ×
Sep 30, 2023 = × × ×
Jun 30, 2023 = × × ×
Mar 31, 2023 = × × ×
Dec 31, 2022 = × × ×
Sep 30, 2022 = × × ×
Jun 30, 2022 = × × ×
Mar 31, 2022 = × × ×

Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).


The financial performance, as disaggregated through a four-component DuPont analysis, reveals several noteworthy trends over the observed period. Return on Assets (ROA) experienced initial stability followed by a gradual decline, with some recent signs of potential stabilization. This overall trend is influenced by movements in the EBIT Margin, Asset Turnover, Interest Burden, and Tax Burden.

Return on Assets (ROA)
ROA began at 6.21% in March 2022 and generally decreased to 4.40% by March 2025. A slight recovery is then observed, reaching 4.66% by December 2025. This suggests a period of diminishing profitability relative to asset base, followed by a potential stabilization.
EBIT Margin
The EBIT Margin demonstrated a consistent decline from 6.24% in March 2022 to 4.11% in December 2025. While fluctuations occurred quarterly, the overall trajectory is downward, indicating decreasing operational profitability. The rate of decline appears to accelerate in the latter half of the period.
Asset Turnover
Asset Turnover exhibited a generally increasing trend, starting at 1.42 in March 2022 and rising to 1.63 in December 2025. This indicates improving efficiency in utilizing assets to generate revenue. The increases were not consistent each quarter, but the overall trend is positive. This positive trend partially offsets the negative impact of the declining EBIT Margin on ROA.
Interest Burden
The Interest Burden remained relatively stable for most of the period, fluctuating between 0.88 and 0.91. A slight decrease is observed towards the end of the period, falling to 0.83 by December 2025. This suggests a minimal change in the proportion of EBIT consumed by interest expense, though the slight decrease could contribute marginally to ROA improvement.
Tax Burden
The Tax Burden remained consistently high, generally around 0.77-0.78, with a slight increase to 0.84 in December 2025. This indicates a relatively stable effective tax rate, and the recent increase would contribute to the decline in ROA.

The decline in ROA is primarily driven by the decreasing EBIT Margin, despite improvements in Asset Turnover. The stable, and recently increasing, Tax Burden further exacerbates this effect. The slight decrease in Interest Burden offers a minor offsetting influence. The recent stabilization in ROA, observed in the final period, may be attributable to the combined effect of improved asset turnover and a slight reduction in interest burden, though the declining EBIT margin continues to exert downward pressure.


Disaggregation of Net Profit Margin

Elevance Health Inc., decomposition of net profit margin ratio (quarterly data)

Microsoft Excel
Net Profit Margin = Tax Burden × Interest Burden × EBIT Margin
Dec 31, 2025 = × ×
Sep 30, 2025 = × ×
Jun 30, 2025 = × ×
Mar 31, 2025 = × ×
Dec 31, 2024 = × ×
Sep 30, 2024 = × ×
Jun 30, 2024 = × ×
Mar 31, 2024 = × ×
Dec 31, 2023 = × ×
Sep 30, 2023 = × ×
Jun 30, 2023 = × ×
Mar 31, 2023 = × ×
Dec 31, 2022 = × ×
Sep 30, 2022 = × ×
Jun 30, 2022 = × ×
Mar 31, 2022 = × ×

Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).


The financial performance metrics reveal discernible trends in profitability over the observed period. A consistent disaggregation of net profit margin, through examination of the tax and interest burdens alongside the EBIT margin, provides insight into the drivers of these trends.

Tax Burden
The tax burden remained remarkably stable between March 31, 2022, and December 31, 2023, consistently around 0.77 to 0.78. A slight decrease to 0.76 was noted in the periods ending March 31, 2024, and June 30, 2024, before returning to 0.78 by September 30, 2025, and increasing to 0.84 by December 31, 2025. This suggests a relatively consistent tax rate with a potential for increased tax obligations towards the end of the observation window.
Interest Burden
The interest burden exhibited a gradual decline from 0.91 in the first three quarters of 2022 to 0.83 by December 31, 2025. This indicates an improving ability to cover interest expenses, potentially due to debt reduction or refinancing at more favorable rates. The decrease, while consistent, is relatively modest.
EBIT Margin
The EBIT margin demonstrated a general downward trend from 6.24% in March 2022 to 4.11% in December 2025. While fluctuations occurred within this period, with a slight recovery to 5.66% in June 2024, the overall trajectory is negative. This suggests increasing operational pressures or declining profitability from core business activities. The most significant decline occurred between March 2023 and December 2025.
Net Profit Margin
The net profit margin mirrored the trend observed in the EBIT margin, declining from 4.37% in March 2022 to 2.87% in December 2025. Similar to the EBIT margin, a temporary increase was observed in June 2024 (3.93%), but the overall trend is downward. The consistent decline in net profit margin, coupled with the stable tax burden and decreasing interest burden, strongly suggests that the primary driver of reduced profitability is a deterioration in operational performance as reflected in the EBIT margin. The impact of the decreasing interest burden was insufficient to offset the decline in EBIT margin and the slight increase in tax burden at the end of the period.

In summary, the analysis indicates a consistent erosion of profitability over the period, primarily attributable to declining operational efficiency as evidenced by the decreasing EBIT margin. While the interest burden decreased, and the tax burden remained relatively stable, these factors did not prevent the overall decline in net profit margin.